NUWE
NuwellisCDocument history
Transcripts and related coverage stored for NUWE. Related articles may discuss other companies and are not verified issuer releases.
Related articleQuarter not tagged2026-11-12Nuwellis (NUWE) Q3 2026 Earnings Call Transcript
Motley Fool
Nuwellis (NUWE) Q3 2026 Earnings Call Transcript
Image source: The Motley Fool. Thursday, Nov. 12, 2026 - Director of Communications - Leah McMullen - President and Chief Executive Officer - Michael McCormick - Chief Financial Officer - Carisa Schultz Operator: Good morning, and welcome to Nuwellis Third Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Participants on this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A replay of the call will be available approximately 1 hour after the end of the call. I would now like to turn the conference over to Leah McMullen, Director of Communications. Please go ahead. Leah McMullen: Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter of 2026. Joining me today are Mike McCormick, Nuwellis' President and Chief Executive Officer; and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its third quarter 2026 financial results. If you have not received the earnings release, please visit the Investors page of the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends as well as our estimated results or performance or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place any undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike McCormick, Nuwellis' CEO. Michael McCormick: Thank you, Leah, and go…Read full documentShow less
Image source: The Motley Fool. Thursday, Nov. 12, 2026 - Director of Communications - Leah McMullen - President and Chief Executive Officer - Michael McCormick - Chief Financial Officer - Carisa Schultz Operator: Good morning, and welcome to Nuwellis Third Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Participants on this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded for playback purposes. A replay of the call will be available approximately 1 hour after the end of the call. I would now like to turn the conference over to Leah McMullen, Director of Communications. Please go ahead. Leah McMullen: Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter of 2026. Joining me today are Mike McCormick, Nuwellis' President and Chief Executive Officer; and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its third quarter 2026 financial results. If you have not received the earnings release, please visit the Investors page of the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends as well as our estimated results or performance or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place any undue reliance on these statements. Please refer to the cautionary statements and discussion of risks in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike McCormick, Nuwellis' CEO. Michael McCormick: Thank you, Leah, and good morning, everyone. On our last conference call, I outlined 3 priorities for Nuwellis. First, to increase Aquadex utilization and recurring circuit revenue; second, to build on our strong position in pediatrics and expand our presence in adult critical care; and third, to strategically broaden our cardiorenal platform through technologies and collaborations that complement the Aquadex and leverage our existing customer relationships. From a financial standpoint, we made meaningful progress in the quarter, improving our operating performance. The third quarter gross margin expanded 430 basis points, while operating expenses declined 13% year-over-year, resulting in a 24% improvement in operating loss. These results reflect our continued focus on disciplined spending, improved operating efficiency and directing resources toward the highest priority growth initiatives. This expansion -- the expansion of our installed base remains one of our most important indicators of our commercial progress. During the first 9 months of 2026, we sold 32 Aquadex consoles. That's an 88% increase compared with 17 consoles during the same period last year. In the third quarter, we sold 8 consoles compared to 12 in the prior year quarter. Every console added to our installed base expands the opportunity for recurring circuit revenue, and our teams remain focused on increasing utilization across our existing hospital customers. We had a strong first half of 2026. And while the second half of the year faces more challenging comparisons against a strong half -- second half in 2025, we remain encouraged by the underlying momentum of our business. The third quarter comparison was particularly challenging because last year, we benefited from approximately $400,000 in accumulated back orders that were fulfilled during the quarter. Excluding that unusual benefit, the underlying performance grew at 20%, and it continues to demonstrate positive momentum going forward. As we have said over the course of the last 2 quarters, pediatric remains our growth driver. Pediatric net sales increased 20% in the third quarter and 26% year-to-date compared with other periods. We also achieved 2 important milestones in our pediatric strategy. First, the results of the ULTRA-Peds Registry. That is a multicenter study. It was titled Kidney Support in Infants and Children Using Aquadex: Findings from the ULTRA-Peds Registry, and it was accepted for publication in a leading peer-reviewed journal, the Pediatric Nephrology. This is an important scientific publication for Nuwellis. The study evaluated 91 pediatric patients treated with Aquadex across 7 children's hospitals with 62% of the patients weighing less than 10 kilograms. Importantly, 87% of those patients survived their Aquadex treatment course, and 86.5% of those procedures were completed without interruption. Beyond these clinical findings, the publication played a really important role in our regulatory strategy. The ULTRA-Peds data served as a cornerstone to our pre-submission meeting with the FDA, allowing us to use peer-reviewed scientific clinical journals as well as real-world evidence to support our proposed expansion of the Aquadex pediatric indication. Following these discussions, on November 5, we submitted to the FDA a 510(k) application to expand the Aquadex SmartFlow system indication from patients weighing 20 kilograms and above to patients weighing as low as 5 kilograms and above. If cleared, this expanded indication would allow us to serve a significantly broader pediatric population, increase access for existing customers and create opportunities for adoption at additional children's hospitals. Our third priority is focused on broadening the product offering for our cardiorenal platform. On our last call, I mentioned that we were evaluating some complementary pediatric technologies that could leverage our commercial infrastructure. I am pleased to say that we have delivered on that commitment with 2 agreements to add to our existing portfolio. In August, we entered into a co-promotion and distribution agreement with Atrility Medical for its AtriAmp postoperative cardiac rhythm monitoring device. AtriAmp is a natural fit for our pediatric and critical care sales force, which already calls on cardiac surgery and critical care teams who care for these patients. We're off to a strong start. Within the short time since signing the agreement, our teams have already completed multiple sales and service calls together, and customer response has been very encouraging. We have a growing pipeline of accounts that are actively in process, which positions us well for growth as we move into 2027. I'm also pleased to announce that earlier this week, we secured exclusive U.S. distribution rights for the pediatric Zorro-Flow external urine collection system. Accurate urine output measurement is central to fluid management in critically ill children, and Zorro-Flow complements our clinical workflows around the Aquadex therapy. We expect to launch this product in the first quarter of 2027. Together, these agreements expand our product portfolio without significant capital required and leverage our existing commercial team and customer relationships. Turning to our internal development programs. We continue to make strong progress on several initiatives designed to expand the capabilities of our Aquadex platform. Aquadex SmartView, our next-generation user interface, is currently under development with an expected launch in the first quarter of 2027. SmartView is designed to improve the user experience and provide a foundation for future enhancements to the Aquadex system. We are also making strong progress on the Aquadex Pressure IQ, which is being developed to expand operating capabilities of Aquadex across additional patient conditions and clinical settings. We expect the Pressure IQ to launch in the first half of 2027. In addition, development of Clarity Prime, our automated kidney function monitoring technology acquired through Rendiatech, continues to advance. We believe this unique technology has the potential application beyond kidney function monitoring, and we are evaluating opportunities to incorporate its capability into other products and clinical applications. Together, these programs reflect our continued commitment to innovation, expanding the clinical utility of Aquadex and creating additional long-term opportunities for our technology platform. In October, we participated in 4 medical conferences, spanning pediatrics, critical care, heart failure and heart failure. Most notable of those 4 conferences is the American Society of Nephrology's Kidney Week. Fluid overload is a common challenge across all 3 markets, and these meetings let our team engage directly with clinicians treating these patients. Our focus is to turn that engagement into new accounts and increase Aquadex utilization. Finally, capital discipline remains central to how we operate. As I mentioned, we reduced operating expenses both year-over-year and sequentially, and our gross margin expanded to 70% in the quarter, reflecting higher average selling prices and continued benefits of our contract manufacturing model. We strengthened our balance sheet during the quarter, and we ended the period with $8.3 million in cash and cash equivalents, providing runway through the second quarter of 2027. With that, I will turn the call over to Carisa Schultz, our Chief Financial Officer, to review our financial results. Carisa Schultz: Thank you, Mike, and good morning. I will review our third quarter and year-to-date financial performance and balance sheet position. Revenue for the third quarter of 2026 was $2.2 million, unchanged from the prior year quarter. As Mike mentioned, the prior year quarter was a challenging comparison period as it included approximately $0.4 million in back order fulfillment. Sequentially, third quarter revenue increased approximately 12% from the second quarter of 2026. Revenue for the first 9 months of 2026 was $6.6 million, an increase of 13% from the prior year, driven by growth in U.S. circuit and console sales. Pediatric net sales increased 20% in the third quarter and 26% for the first 9 months compared with the prior year period. In the first 9 months of 2026, we sold 32 consoles compared with 17 in the prior year period, an 88% increase. During the quarter, the company sold 8 Aquadex consoles compared with 12 in the third quarter of 2025. Gross profit for the third quarter of 2026 was approximately $1.5 million, resulting in a gross margin of 70% compared with 65% in the prior year quarter. The expanded margin improvement was driven by higher circuit and console average selling prices, favorable product mix and the benefits of our transition to contract manufacturing. Operating expenses for the third quarter were approximately $3.6 million compared with approximately $4.1 million in the prior year quarter and approximately $4.7 million in the second quarter of 2026. The year-over-year decrease primarily reflects reductions in administrative costs and lower sales-related compensation. The sequential decrease reflects our continued efforts to align expenses with the company's highest priority commercial and strategic programs. The combination of gross margin expansion and disciplined expense management resulted in a 24% year-over-year improvement in operating loss from approximately $2.7 million to $2.1 million. We remain focused on reducing operating expenses and cash utilization while continuing to invest in commercial and development programs that offer the greatest potential for long-term growth. Reported net loss for the third quarter was approximately $2 million compared with net income of approximately $0.5 million in the prior year quarter. The prior year result included a significant noncash gain associated with changes in the fair value of warrant liabilities. Turning to the balance sheet. As of September 30, 2026, the company had cash and cash equivalents of approximately $8.3 million with runway through the second quarter of next year. During the third quarter, we raised $3.4 million in gross proceeds through a registered direct offering in July and concurrently received $3.3 million in gross proceeds from the cash exercise of warrants. We also received $1.4 million in net proceeds from common shares sold under our at-the-market program. Looking ahead, our financial priorities remain unchanged, increasing recurring circuit revenue, reducing cash utilization and directing capital toward the commercial and development programs with the greatest potential to create value. That concludes my prepared remarks. I will now turn the call back to Mike. Michael McCormick: Thank you, Carisa. Before opening the call to questions, I want to take a second and just summarize where Nuwellis stands year-to-date. We have grown by double digits, nearly doubled our unit console sales and significantly expanded our gross margin while reducing operating expenses and strengthening our balance sheet. In pediatrics, we have strengthened our clinical foundation with the ULTRA-Peds peer-reviewed publication, and we built on that evidence by submitting our 510(k) seeking expanded indications for the Aquadex to patients weighing as little as 5 kilograms. We are also advancing product development pipeline with SmartView and Pressure IQ that are expected to launch in 2027 while continuing to develop Clarity Prime and exploring additional applications for that technology. And we broadened our commercial portfolio with agreements with Atrility Medical and Zorro-Flow, adding complementary products that leverage our existing sales force and customer relationships in a capital-efficient way. We believe this progress positions Nuwellis for sustained growth and long-term value creation for patients, customers and shareholders. We remain focused on disciplined execution and delivering measurable progress against each of these priorities. Operator, we'd now like to open the call to any questions. Operator: [Operator Instructions] And at this time, we show no questions in queue. I will now turn the call back to Mike for some concluding remarks. Michael McCormick: Thank you. We appreciate everybody's participation today and updating you on the third quarter results. We look forward to continue to update you on our progress and discussing the fourth quarter financial results at our next conference call early next year. Thank you again for joining us today. Operator: Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect. Before you buy stock in Nuwellis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nuwellis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $348,060!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,067,492!* Now, it's worth noting Stock Advisor's total average return is 849% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of November 12, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Nuwellis (NUWE) Q3 2026 Earnings Call Transcript was originally published by The Motley Fool
Related articleQuarter not tagged2026-11-12Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
GlobeNewswire
Nuwellis Reports Third Quarter 2026 Financial Results and Business Update Highlighted by 430 Basis Point Gross Margin Expansion and 13% Reduction in Operating Expenses, Driving 24% Improvement in Operating Loss
Console unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue Advanced growth strategy with 510(k) submission for Aquadex label expansion and two product portfolio-expanding agreements leveraging existing sales force Company to conduct conference call beginning at 9:00 a.m. Eastern time today MINNEAPOLIS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026. Third Quarter 2026 Financial Highlights - Operating loss for the third quarter of 2026 improved 24% year over year to $2.1 million, driven by 430 basis points of gross margin expansion and a 13% reduction in operating expenses, primarily reflecting outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs. - Net sales were $2.2 million in the third quarter of 2026, essentially unchanged versus the prior-year quarter, as the prior-year period benefited from fulfilling $0.4 million in accumulated backorders. Net sales increased 12% sequentially in the third quarter of 2026. For the nine months ended September 30, 2026, net sales increased 13% to $6.6 million compared with $5.8 million in the prior-year period, driven by growth in U.S. circuit and console sales. - Pediatrics remained a significant growth driver, with net sales increasing 20% in the third quarter of 2026 and 26% year-to-date, compared with the prior-year periods. - Sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase compared with 17 consoles in the prior-year period. The expanded installed base provides a strong foundation for future recurring circuit revenue. - Third-quarter 2026 gross margin expanded to 69.5% from 65.2% in the prior-year quarter, reflecting higher average selling prices and continued benefits from the Company's contract manufacturing model. Year-to-date gross margin improved to 71.7%, compared with 59.4% in the prior-year period. - Strengthened the Company's balance sheet as of September 30, 2026, with $8.3 million in cash and cash equivalents. Business Updates - Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA)…Read full documentShow less
Console unit sales increased 88% year-to-date versus prior-year period, expanding its installed base to drive future recurring circuit revenue Advanced growth strategy with 510(k) submission for Aquadex label expansion and two product portfolio-expanding agreements leveraging existing sales force Company to conduct conference call beginning at 9:00 a.m. Eastern time today MINNEAPOLIS, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and nine months ended September 30, 2026. Third Quarter 2026 Financial Highlights - Operating loss for the third quarter of 2026 improved 24% year over year to $2.1 million, driven by 430 basis points of gross margin expansion and a 13% reduction in operating expenses, primarily reflecting outsourced manufacturing efficiencies and efforts to align expenses with the highest-priority commercial and strategic programs. - Net sales were $2.2 million in the third quarter of 2026, essentially unchanged versus the prior-year quarter, as the prior-year period benefited from fulfilling $0.4 million in accumulated backorders. Net sales increased 12% sequentially in the third quarter of 2026. For the nine months ended September 30, 2026, net sales increased 13% to $6.6 million compared with $5.8 million in the prior-year period, driven by growth in U.S. circuit and console sales. - Pediatrics remained a significant growth driver, with net sales increasing 20% in the third quarter of 2026 and 26% year-to-date, compared with the prior-year periods. - Sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase compared with 17 consoles in the prior-year period. The expanded installed base provides a strong foundation for future recurring circuit revenue. - Third-quarter 2026 gross margin expanded to 69.5% from 65.2% in the prior-year quarter, reflecting higher average selling prices and continued benefits from the Company's contract manufacturing model. Year-to-date gross margin improved to 71.7%, compared with 59.4% in the prior-year period. - Strengthened the Company's balance sheet as of September 30, 2026, with $8.3 million in cash and cash equivalents. Business Updates - Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking to expand the indication of its Aquadex SmartFlow® System to include pediatric patients weighing five kilograms and above. - A multicenter study titled "Kidney Support in Infants and Children using Aquadex: Findings From the ULTRA-Peds Registry" was accepted for publication in Pediatric Nephrology. - Entered into a co-promotion and distribution agreement with Atrility Medical for its AtriAmp postoperative cardiac rhythm monitoring device, which leverages Nuwellis' current pediatric and critical care sales force. - Secured a second strategic distribution agreement with the exclusive U.S. distribution rights for the pediatric Zorro-Flow™ external urine collection system. "We have made meaningful progress in strengthening Nuwellis both commercially and financially. Year to date, console unit sales have nearly doubled, expanding our installed base and creating a larger opportunity to grow recurring circuit revenue. Although our third quarter faced a tough comparison against the prior-year period when we fulfilled a significant backorder, the underlying momentum in our business remains strong, as evidenced by the growth in our pediatric segment," said Mike McCormick, Nuwellis President and Chief Executive. "Further, by expanding gross margins and maintaining disciplined cost management, we significantly narrowed our operating loss and cash use during the quarter while continuing to invest in the areas that matter most to our long-term growth. "We also delivered on several key strategic initiatives, including the submission of a 510(k) to the FDA to expand the Aquadex label to pediatric patients weighing as little as five kilograms, which, if cleared, could expand access and increase adoption. In addition, we secured distribution agreements with Atrility Medical and Zorro-Flow, which broaden our product offering in a capital-efficient manner through our established commercial infrastructure. We believe these achievements position Nuwellis for sustainable growth and long-term value creation for patients, customers and shareholders." Third Quarter 2026 Financial Results Net sales for the third quarter of 2026 were $2.2 million, unchanged from the prior-year quarter, primarily due to a $0.4 million backorder in the third quarter of 2025. Net sales increased approximately 12% sequentially from the second quarter of 2026. In the third quarter of 2026, the pediatric segment demonstrated continued strength with an increase in net sales of 20% versus the prior-year period. The Company sold eight Aquadex consoles during the third quarter, compared with 12 in the prior-year quarter. Through the first nine months of 2026, the Company sold 32 consoles, compared with 17 during the comparable 2025 period. Gross margin for the third quarter of 2026 was 69.5%, compared with 65.2% in the prior-year quarter. The improvement reflected increased average selling prices and benefits from the Company's transition to contract manufacturing. Operating expenses decreased to $3.6 million from $4.1 million in the prior-year quarter, reflecting continued expense management and operational efficiencies. In the third quarter of 2026, loss from operations improved 24% to $2.1 million, compared with $2.7 million in the prior-year quarter. Net loss was $2.0 million, compared with net income of approximately $0.5 million in the prior-year quarter, which included a significant noncash gain associated with changes in the fair value of warrant liabilities. As of September 30, 2026, the Company had cash and cash equivalents of approximately $8.3 million. In July 2026, the Company raised $3.4 million in gross proceeds in a direct offering. Concurrently, the Company received gross proceeds of $3.3 million from the cash exercise of warrants. During the third quarter of 2026, the Company received $1.4 million in net proceeds from common shares sold under its ATM. Webcast and Conference Call Information The Company will host a conference call and webcast at 9:00 a.m. Eastern time today to discuss its third-quarter financial results and provide an update on the Company's performance. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com/. Alternatively, the live conference call may be accessed by dialing (833) 309-3473 or (785) 838-9251 and using conference ID NUWEQ3. An audio archive of the webcast will be available following the call on the Investors page. About Aquadex The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: Investor Relations: CORE IR [email protected] Media Contact: CORE PR [email protected] NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | | | | | | | | September 30, | | | December 31, 2025 | | 2026 | | ASSETS | | (Unaudited) | | | | Current assets | | | | | | Cash and cash equivalents | $ | 8,290 | | $ | 1,085 | Accounts receivable | | 1,391 | | | 1,493 | Inventories, net | | 1,770 | | | 1,910 | Other current assets | | 479 | | | 698 | Total current assets | | 11,930 | | | 5,186 | Property, plant and equipment, net | | 303 | | | 368 | Operating lease right-of-use asset | | 120 | | | 293 | Intangible assets, net | | 93 | | | — | Other assets | | 999 | | | 271 | TOTAL ASSETS | $ | 13,445 | | $ | 6,118 | | | | | | | LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY | | | | | | Current liabilities | | | | | | Accounts payable and accrued liabilities | $ | 1,986 | | $ | 2,226 | Accrued compensation | | 700 | | | 460 | Current portion of operating lease liability | | 135 | | | 261 | Deferred consideration from Rendiatech acquisition, current | | 113 | | | — | Other current liabilities | | 56 | | | 85 | Total current liabilities | | 2,990 | | | 3,032 | Deferred consideration from Rendiatech acquisition, non-current | | 200 | | | — | Warrant liabilities | | 399 | | | 389 | Operating lease liability | | 0 | | | 67 | Total liabilities | | 3,589 | | | 3,488 | Commitments and contingencies | | | | | | | | | | | | Mezzanine Equity | | | | | | Series J Convertible Preferred Stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 600,000 shares, issued and outstanding 170 and 137, respectively | | 11 | | 6 | | | | Stockholders' equity | | | | | | Series A junior participating preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 30,000 shares, none outstanding | | — | | | — | Series F convertible preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 18,000 shares, issued and outstanding 27 and 127 shares, respectively | | — | | | — | Series F-1 convertible preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100 shares, issued and outstanding 34 and 34 shares, respectively | | — | | | — | Preferred stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 39,352,000 shares, none outstanding | | — | | | — | Common stock as of September 30, 2026 and December 31, 2025, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 540,912 and 5,342, respectively | | — | | | — | Additional paid-in capital | | 337,487 | | | 318,928 | Accumulated other comprehensive income: | | | | | | Foreign currency translation adjustment | | 8 | | | 8 | Accumulated deficit | | (327,650 | ) | | (316,312 | ) Total stockholders' equity | | 9,845 | | | 2,624 | TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY | $ | 13,445 | | $ | 6,118 | NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except per share amounts and weighted average shares outstanding) | | | | | | Three months ended | Nine months ended | | September 30, | September 30, | | | | 2026 | | 2025 | | 2026 | | 2025 | Net sales | | $ | 2,212 | | $ | 2,217 | | $ | 6,584 | | $ | 5,846 | Cost of goods sold | | | 674 | | | 772 | | | 1,864 | | | 2,376 | Gross profit | | | 1,538 | | | 1,445 | | | 4,720 | | | 3,470 | Operating expenses: | | | | | | | | | | | | | Selling, general and administrative | | | 3,007 | | | 3,539 | | | 11,256 | | | 10,305 | Research and development | | | 584 | | | 603 | | | 3,254 | | | 1,828 | Total operating expenses | | | 3,591 | | | 4,142 | | | 14,510 | | | 12,133 | Loss from operations | | | (2,053 | ) | | (2,697 | ) | | (9,790 | ) | | (8,663 | ) Other income | | | 51 | | | 4 | | | 59 | | | 21 | Financing expense | | | (61 | ) | | - | | | (6,138 | ) | | (10,553 | ) Change in fair value of warrant liabilities | | | 94 | | | 3,161 | | | 4,531 | | | 4,101 | (Loss) income before income taxes | | | (1,969 | ) | | 468 | | | (11,338 | ) | | (15,094 | ) Income tax expense | | | - | | | - | | | - | | | (5 | ) Net (loss) income | | $ | (1,969 | ) | $ | 468 | | $ | (11,338 | ) | $ | (15,099 | ) Deemed dividend attributable to Series J Convertible Preferred Stock | | | 2 | | | 1 | | | 5 | | | 3 | Net (loss) income attributable to common shareholders | | $ | (1,967 | ) | $ | 469 | | $ | (11,333 | ) | $ | (15,096 | ) | | | | | | | | | | | | | Basic and diluted (loss) income per share | | $ | (5.81 | ) | $ | 177.16 | | $ | ( 93.13 | ) | $ | (12,548.83 | ) | | | | | | | | | | | | | Weighted average shares outstanding – basic and diluted | | | 338,384 | | | 2,646 | | | 121,695 | | | 1,203 | | | | | | | | | | | | | | Other comprehensive loss: | | | | | | | | | | | | | Net (loss) income | | $ | (1,969 | ) | | 468 | | | (11,338 | ) | | (15,099 | ) Foreign currency translation adjustments | | | - | | | (1 | ) | | - | | | (7 | ) Total comprehensive (loss) income | | $ | (1,969 | ) | $ | 467 | | $ | (11,338 | ) | $ | (15,106 | ) NUWELLIS, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) | | Nine Months ended | September 30, | | 2026 | | | | 2025 | Operating Activities: | | | | | Net loss | $ | (11,338 | ) | | $ | (15,099 | ) Adjustments to reconcile net loss to cash flows used in operating activities: | | | | | Depreciation and amortization | | 107 | | | | 166 | Stock-based compensation expense | | 55 | | | | 103 | Change in fair value of warrant liabilities | | (4,531 | ) | | | (4,101 | ) Financing expense | | 6,138 | | | | 10,553 | Non-cash IP R&D from Rendiatech acquisition | | 757 | | | | - | Changes in operating assets and liabilities: | | | | | Accounts receivable | | 102 | | | | 586 | Inventory, net | | 190 | | | | (471 | ) Other current assets | | 219 | | | | (461 | ) Other assets | | (554 | ) | | | 108 | Other liabilities | | (221 | ) | | | (74 | ) Accounts payable and accrued expenses | | (196 | ) | | | 910 | Net cash used in operating activities | | (9,272 | ) | | | (7,780 | ) | | | | | Investing Activities: | | | | | Purchases of property and equipment | | (17 | ) | | | (102 | ) Purchase of intangible assets | | (90 | ) | | | - | Cash paid for acquisition of Rendiatech, net of cash acquired | | (164 | ) | | | - | Net cash used in investing activities | | (271 | ) | | | (102 | ) | | | | | Financing Activities: | | | | | Proceeds from issuance of common stock and warrants, net | | 15,392 | | | | 3,999 | Issuance of common stock from ATM, net | | 1,358 | | | | 1,889 | Net cash provided by financing activities | | 16,750 | | | | 5,888 | | | | | | Effect of exchange rate changes on cash | | — | | | | (7 | ) Net increase (decrease) in cash and cash equivalents | | 7,207 | | | | (2,001 | ) Cash and cash equivalents, and restricted cash - beginning of period | | 1,190 | | | | 5,095 | Cash and cash equivalents, and restricted cash - end of period | $ | 8,397 | | | $ | 3,094 | | | | | | Cash and cash equivalents – end of period | | 8,290 | | | | 3,094 | Restricted cash – end of period | | 107 | | | | -- | Cash and cash equivalents, and restricted cash – end of period | $ | 8,397 | | | $ | 3,094 | Supplemental cash flow information | | | | | | | Series C warrant conversion to equity | $ | 5,031 | | $ | | - | Series D warrant exercises | $ | 1,438 | | $ | | - | Deferred costs issued as consideration in asset acquisition | $ | 313 | | $ | | - | Common stock issued as consideration in asset acquisition | $ | 162 | | $ | | - | Series A warrants conversion to equity | $ | - | | $ | | 8,439 | Series B warrant exercises | $ | - | | $ | | 2,055 | Issuance of common stock for conversion of Series F-1 Preferred Stock | $ | - | | $ | | 1,100 | Deemed dividend on Series J Preferred Stock | $ | 5 | | $ | | 3 | | | | | | |
Related articleQuarter not tagged2026-11-12Nuwellis, Inc. Q3 2026 Earnings Call Summary
Moby
Nuwellis, Inc. Q3 2026 Earnings Call Summary
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. - Gross margin expanded 430 basis points to 70% in the quarter, driven by higher average selling prices, favorable product mix, and the continued benefits of the transition to a contract manufacturing model. - Operating loss improved by 24% year-over-year as management reduced operating expenses by 13% through disciplined spending and alignment of resources toward high-priority growth initiatives. - Pediatric sales grew 20% in the quarter and 26% year-to-date, serving as the company's primary growth driver and supported by the publication of the ULTRA-Peds Registry in a peer-reviewed journal. - The company is broadening its cardiorenal platform through capital-efficient co-promotion and distribution agreements for AtriAmp and Zorro-Flow, leveraging the existing sales force and customer relationships. - Year-to-date console sales increased 88% compared to the prior year, which management views as a critical indicator for expanding future recurring circuit revenue. - Management attributed the flat year-over-year revenue comparison to a one-time $400,000 backorder fulfillment in the prior year quarter, noting that underlying performance grew by 20% when excluding that benefit. - A 510(k) application was submitted to the FDA to expand the Aquadex SmartFlow system indication to include patients weighing as low as 5 kilograms, significantly broadening the addressable pediatric population. - Management expects a sequence of product launches in early 2027, including the Aquadex SmartView user interface and the Zorro-Flow external urine collection system in Q1, followed by Pressure IQ in the first half of the year. - Current cash and cash equivalents of $8.3 million are expected to provide a financial runway through the second quarter of 2027. - The company is evaluating opportunities to incorporate Clarity Prime's automated kidney function monitoring technology into other products and clinical applications beyond its original scope. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. - The reported net loss of $2 million compared to a prior year net income was primarily due to a significant non-cash gain from warrant liability fair value changes in the 2025 period.…Read full documentShow less
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. - Gross margin expanded 430 basis points to 70% in the quarter, driven by higher average selling prices, favorable product mix, and the continued benefits of the transition to a contract manufacturing model. - Operating loss improved by 24% year-over-year as management reduced operating expenses by 13% through disciplined spending and alignment of resources toward high-priority growth initiatives. - Pediatric sales grew 20% in the quarter and 26% year-to-date, serving as the company's primary growth driver and supported by the publication of the ULTRA-Peds Registry in a peer-reviewed journal. - The company is broadening its cardiorenal platform through capital-efficient co-promotion and distribution agreements for AtriAmp and Zorro-Flow, leveraging the existing sales force and customer relationships. - Year-to-date console sales increased 88% compared to the prior year, which management views as a critical indicator for expanding future recurring circuit revenue. - Management attributed the flat year-over-year revenue comparison to a one-time $400,000 backorder fulfillment in the prior year quarter, noting that underlying performance grew by 20% when excluding that benefit. - A 510(k) application was submitted to the FDA to expand the Aquadex SmartFlow system indication to include patients weighing as low as 5 kilograms, significantly broadening the addressable pediatric population. - Management expects a sequence of product launches in early 2027, including the Aquadex SmartView user interface and the Zorro-Flow external urine collection system in Q1, followed by Pressure IQ in the first half of the year. - Current cash and cash equivalents of $8.3 million are expected to provide a financial runway through the second quarter of 2027. - The company is evaluating opportunities to incorporate Clarity Prime's automated kidney function monitoring technology into other products and clinical applications beyond its original scope. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. - The reported net loss of $2 million compared to a prior year net income was primarily due to a significant non-cash gain from warrant liability fair value changes in the 2025 period. - During the third quarter, the company strengthened its balance sheet by raising approximately $8.1 million in total proceeds through a registered direct offering, warrant exercises, and an at-the-market program.
Related articleQuarter not tagged2026-11-12Nuwellis Inc (NUWE) (Q3 2026) Earnings Call Highlights: Margin Expansion and Pediatric Growth ...
GuruFocus.com
Nuwellis Inc (NUWE) (Q3 2026) Earnings Call Highlights: Margin Expansion and Pediatric Growth ...
This article first appeared on GuruFocus. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Gross margin expanded 430 basis points year-over-year to 70% in Q3 2026, driven by higher average selling prices and contract manufacturing benefits. - Operating expenses declined 13% year-over-year and sequentially, reflecting disciplined cost management. - Operating loss improved 24% year-over-year, from $2.7 million to $2.1 million. - Console sales for the first nine months of 2026 increased 88% to 32 units, compared to 17 in the prior year period. - Pediatric net sales grew 20% in Q3 and 26% year-to-date, with a peer-reviewed publication of the ULTRAPED registry and a 510(k) submission to expand the Aquadex indication to patients weighing as low as 5 kg. - Balance sheet strengthened with $8.3 million in cash and cash equivalents, providing runway through Q2 2027. - Strategic portfolio expansion through agreements with Trility Medical (AtriAmp) and exclusive U.S. distribution rights for the pediatric Xoroflow system, leveraging existing sales force. - Product development pipeline advancing with SmartView and Pressure IQ expected to launch in 2027, and Clarity Prime technology under development. - Q3 2026 revenue was flat at $2.2 million compared to the prior year quarter, which included a $0.4 million backorder benefit; excluding that, underlying growth was 20%. - Console sales in Q3 2026 declined to 8 units from 12 in the prior year quarter. - Net loss for Q3 2026 was approximately $2 million, compared to net income of $0.5 million in the prior year quarter (which included a non-cash gain). - The company remains unprofitable with an operating loss of $2.1 million in Q3 2026. - Cash runway is limited to through Q2 2027, indicating potential need for additional financing. - Revenue growth in the second half of 2026 faces challenging comparisons against a strong second half of 2025. - The 510(k) submission for expanded pediatric indication is pending FDA clearance, with no guarantee of approval. - New product launches (SmartView, Pressure IQ, Xoroflow) are not expected until 2027, limiting near-term revenue contribution. - Warning! GuruFocus has detected 5 Warning Signs with NUWE. - Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: How did Nuwellis perform fina…Read full documentShow less
This article first appeared on GuruFocus. Release Date: November 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. - Gross margin expanded 430 basis points year-over-year to 70% in Q3 2026, driven by higher average selling prices and contract manufacturing benefits. - Operating expenses declined 13% year-over-year and sequentially, reflecting disciplined cost management. - Operating loss improved 24% year-over-year, from $2.7 million to $2.1 million. - Console sales for the first nine months of 2026 increased 88% to 32 units, compared to 17 in the prior year period. - Pediatric net sales grew 20% in Q3 and 26% year-to-date, with a peer-reviewed publication of the ULTRAPED registry and a 510(k) submission to expand the Aquadex indication to patients weighing as low as 5 kg. - Balance sheet strengthened with $8.3 million in cash and cash equivalents, providing runway through Q2 2027. - Strategic portfolio expansion through agreements with Trility Medical (AtriAmp) and exclusive U.S. distribution rights for the pediatric Xoroflow system, leveraging existing sales force. - Product development pipeline advancing with SmartView and Pressure IQ expected to launch in 2027, and Clarity Prime technology under development. - Q3 2026 revenue was flat at $2.2 million compared to the prior year quarter, which included a $0.4 million backorder benefit; excluding that, underlying growth was 20%. - Console sales in Q3 2026 declined to 8 units from 12 in the prior year quarter. - Net loss for Q3 2026 was approximately $2 million, compared to net income of $0.5 million in the prior year quarter (which included a non-cash gain). - The company remains unprofitable with an operating loss of $2.1 million in Q3 2026. - Cash runway is limited to through Q2 2027, indicating potential need for additional financing. - Revenue growth in the second half of 2026 faces challenging comparisons against a strong second half of 2025. - The 510(k) submission for expanded pediatric indication is pending FDA clearance, with no guarantee of approval. - New product launches (SmartView, Pressure IQ, Xoroflow) are not expected until 2027, limiting near-term revenue contribution. - Warning! GuruFocus has detected 5 Warning Signs with NUWE. - Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: How did Nuwellis perform financially in Q3 2026, and what drove the improvement in operating loss? A: CFO Carisa Schultz reported Q3 2026 revenue of $2.2 million, unchanged year-over-year due to a challenging comparison that included approximately $400,000 in prior-year backorder fulfillment. However, gross margin expanded to 70% from 65%, and operating expenses fell to $3.6 million from $4.1 million, driving a 24% year-over-year improvement in operating loss from approximately $2.7 million to $2.1 million. Q: What is the status of the FDA submission to expand the Aquadex pediatric indication? A: CEO Mike McCormick said Nuwellis submitted a 510(k) application to the FDA on November 5, 2026, seeking to expand the Aquadex SmartFlow system indication from patients weighing 20 kilograms and above to those weighing as low as 5 kilograms. The submission was supported by the ULTRAPED registry data published in Pediatric Nephrology, which showed 87% survival among 91 pediatric patients treated, 62% of whom weighed less than 10 kilograms. Q: How is the installed base of Aquadex consoles trending, and why does it matter for revenue? A: CEO Mike McCormick said Nuwellis sold 32 Aquadex consoles in the first nine months of 2026, an 88% increase from 17 consoles in the same period last year, though Q3 console sales were eight versus 12 in the prior-year quarter. He noted that every console added to the installed base expands the opportunity for recurring circuit revenue, and the teams remain focused on increasing utilization across existing hospital customers. Q: How is the pediatric business performing, and what is driving its growth? A: CEO Mike McCormick said pediatric remains the company's growth driver, with pediatric net sales up 20% in Q3 2026 and 26% year-to-date. He highlighted the ULTRAPED registry publication in Pediatric Nephrology as an important scientific milestone that also served as a cornerstone of the company's regulatory strategy for the expanded pediatric indication. Q: What complementary products has Nuwellis added to its cardio-renal platform, and when will they contribute? A: CEO Mike McCormick said Nuwellis entered a co-promotion and distribution agreement with Trility Medical in August for the AtriAmp post-operative cardiac rhythm monitoring device, with multiple sales and service calls already completed and a growing pipeline of accounts positioning the company for growth into 2027. He also announced exclusive U.S. distribution rights for the pediatric Xoroflow external urine collection system, expected to launch in Q1 2027. Q: What internal product development programs are underway, and what are their expected launch timelines? A: CEO Mike McCormick said Aquadex SmartView, the next-generation user interface, is under development with an expected launch in Q1 2027, and Aquadex Pressure IQ, designed to expand operating capabilities across additional patient conditions and clinical settings, is expected to launch in the first half of 2027. Development of Clarity Prime, the automated kidney function monitoring technology acquired through Renalytrix, also continues to advance, with the company evaluating broader applications. Q: What is Nuwellis' cash position and financial runway? A: CFO Carisa Schultz said the company ended Q3 2026 with approximately $8.3 million in cash and cash equivalents, providing runway through the second quarter of 2027. During the quarter, Nuwellis raised $3.4 million in gross proceeds through a July registered direct offering, received $3.3 million in gross proceeds from warrant cash exercises, and raised $1.4 million in net proceeds from common shares sold under its at-the-market program. Q: What drove the gross margin expansion in Q3 2026? A: CFO Carisa Schultz said the 430-basis-point year-over-year gross margin expansion to 70% was driven by higher circuit and console average selling prices, favorable product mix, and the benefits of the company's transition to a contract manufacturing model. Q: How should investors view the Q3 revenue comparison, and what is the underlying growth trend? A: CEO Mike McCormick said the Q3 comparison was particularly challenging because the prior-year quarter benefited from approximately $400,000 in accumulated backorders fulfilled during that period. Excluding that unusual benefit, underlying performance grew 20%, and revenue for the first nine months of 2026 rose 13% to $6.6 million, driven by growth in U.S. circuit and console sales. Q: What were the key drivers of the year-over-year and sequential operating expense reductions? A: CFO Carisa Schultz said operating expenses of approximately $3.6 million in Q3 2026 compared with approximately $4.1 million in the prior-year quarter and approximately $4.7 million in Q2 2026. The year-over-year decrease primarily reflected reductions in administrative costs and lower sales-related compensation, while the sequential decrease reflected continued efforts to align expenses with the company's highest priority commercial and strategic programs. Q: What explains the swing from prior-year net income to a net loss in Q3 2026? A: CFO Carisa Schultz said the reported net loss for Q3 2026 was approximately $2 million, compared with net income of approximately $0.5 million in the prior-year quarter. The prior-year result included a significant non-cash gain associated with changes in the fair value of warrant liabilities, which does not reflect operating performance. Q: What are Nuwellis' financial priorities going forward? A: CFO Carisa Schultz said the company's financial priorities remain unchanged: increasing recurring circuit revenue, reducing cash utilization, and directing capital toward the commercial and development programs with the greatest potential to create value. CEO Mike McCormick added that capital discipline remains central to operations, with resources directed toward the highest priority growth initiatives. For the complete transcript of the earnings call, please refer to the full earnings call transcript.
TranscriptFY2026 Q32026-11-12FY2026 Q3 earnings call transcript
Earnings source - 20 paragraphs
FY2026 Q3 earnings call transcript
results and business update conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Participants on this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A replay of the call will be available approximately one hour after the end of the call. I would now like to turn the conference over to Leah McMullen, Director of Communications. Please go ahead.
Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the third quarter of 2026. Joining me today are Mike McCormick, Nuwellis' President and Chief Executive Officer, and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its third quarter 2026 financial results. If you have not received the earnings release, please visit the Investors page of the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to expectations or predictions of future events and market trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place any undue reliance on these statements. Please refer to the cautionary statements and discussion of risk in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike McCormick, Nuwellis CEO.
Thank you, Leah, and good morning, everyone. On our last conference call, I outlined three priorities for Nuwellis. First, to increase Aquadex utilization and recurring circuit revenue. Second, to build on our strong position in pediatrics and expand our presence in adult critical care. Third, to strategically broaden our cardiorenal platform through technologies and collaborations that complement the Aquadex and leverage our existing customer relationships. From a financial standpoint, we made meaningful progress in the quarter, improving our operating performance. The third quarter gross margin expanded 430 basis points, while operating expenses declined 13% year-over-year, resulting in a 24% improvement in operating loss. These results reflect our continued focus on disciplined spending, improved operating efficiency, and directing resources toward the highest priority growth initiatives. The expansion of our installed base remains one of our most important indicators of our commercial progress.
During the first nine months of 2026, we sold 32 Aquadex consoles. That is an 88% increase compared with 17 consoles during the same period last year. In the third quarter, we sold eight consoles compared to 12 in the prior year quarter. Every console added to our installed base expands the opportunity for recurring circuit revenue, and our teams remain focused on increasing utilization across our existing hospital customers. We had a strong first half of 2026, and while the second half of the year faces more challenging comparisons against a strong second half in 2025, we remain encouraged by the underlying momentum of our business. The third quarter comparison was particularly challenging because last year, we benefited from approximately $400,000 in accumulated back orders that were fulfilled during the quarter.
Excluding that unusual benefit, the underlying performance grew at 20%, and it continues to demonstrate positive momentum going forward. As we have said over the course of the last two quarters, pediatric remains our growth driver. Pediatric net sales increased 20% in the third quarter and 26% year-to-date compared with other periods. We also achieved two important milestones in our pediatric strategy. First, the results of the ULTRA-Peds Registry. That is a multicenter study. It was titled "Kidney Support in Infants and Children Using Aquadex: Findings from the ULTRA-Peds Registry," and it was accepted for publication in a leading peer-reviewed journal, the Pediatric Nephrology. This is an important scientific publication for Nuwellis. The study evaluated 91 pediatric patients treated with Aquadex across seven children's hospitals, with 62% of the patients weighing less than 10 kilograms.
Importantly, 87% of those patients survived their Aquadex treatment course, and 86.5% of those procedures were completed without interruption. Beyond these clinical findings, the publication played a really important role in our regulatory strategy. The ULTRA-Peds data served as a cornerstone to our pre-submission meeting with the FDA, allowing us to use peer-reviewed scientific clinical journals, as well as real-world evidence to support our proposed expansion of the Aquadex pediatric indication. Following these discussions, on November 5, we submitted to the FDA a 510(k) application to expand the Aquadex SmartFlow System indication from patients weighing 20 kg and above to patients weighing as low as 5 kg and above. If cleared, this expanded indication would allow us to serve a significantly broader pediatric population, increase access for existing customers, and create opportunities for adoption at additional children's hospitals.
Our third priority is focused on broadening the product offering for our cardiorenal platform. On our last call, I mentioned that we were evaluating some complementary pediatric technologies that could leverage our commercial infrastructure. I am pleased to say that we have delivered on that commitment with two agreements to add to our existing portfolio. In August, we entered into a co-promotion distribution agreement with Atrility Medical for its AtriAmp postoperative cardiac rhythm monitoring device. AtriAmp is a natural fit for our pediatric and critical care sales force, which already calls on cardiac surgery and critical care teams who care for these patients. We are off to a strong start. Within the short time since signing the agreement, our teams have already completed multiple sales and service calls together, and customer response has been very encouraging.
We have a growing pipeline of accounts that are actively in process, which positions us well for growth as we move into 2027. I am also pleased to announce that earlier this week, we secured exclusive U.S. Distribution rights for the pediatric Zorro-Flow external urine collection system. Accurate urine output measurement is central to fluid management in critically ill children, and Zorro-Flow complements our clinical workflows around the Aquadex therapy. We expect to launch this product in the first quarter of 2027. Together, these agreements expand our product portfolio without significant capital required and leverage our existing commercial team and customer relationships. Turning to our internal development programs, we continue to make strong progress on several initiatives designed to expand the capabilities of our Aquadex platform. Aquadex SmartView, our next-generation user interface, is currently under development, with an expected launch in the first quarter of 2027.
SmartView is designed to improve the user experience and provide a foundation for future enhancements to the Aquadex system. We are also making strong progress on the Aquadex Pressure IQ, which is being developed to expand operating capabilities of Aquadex across additional patient conditions and clinical settings. We expect the Pressure IQ to launch in the first half of 2027. In addition, development of ClarityPRIME, our automated kidney function monitoring technology acquired through Rendiatech, continues to advance. We believe this unique technology has the potential application beyond kidney function monitoring, and we are evaluating opportunities to incorporate its capability into other products and clinical applications. Together, these programs reflect our continued commitment to innovation, expanding the clinical utility of Aquadex, and creating additional long-term opportunities for our technology platform. In October, we participated in four medical conferences spanning pediatrics, critical care, and heart failure.
Most notable of those four conferences is the American Society of Nephrology's Kidney Week. Fluid overload is a common challenge across all three markets, and these meetings let our team engage directly with clinicians treating these patients. Our focus is to turn that engagement into new accounts and increase Aquadex utilization. Finally, capital discipline remains central to how we operate. As I mentioned, we reduced operating expenses both year-over-year and sequentially, and our gross margin expanded 430 basis points in the quarter, reflecting higher average selling prices and continued benefits of our contract manufacturing model. We strengthened our balance sheet during the quarter, and we ended the period with $8.3 million in cash and cash equivalents, providing runway through the second quarter of 2027. With that, I will turn the call over to Carisa Schultz, our Chief Financial Officer, to review our financial results.
Thank you, Mike, and good morning. I will review our third quarter and year-to-date financial performance and balance sheet position. Revenue for the third quarter of 2026 was $2.2 million, unchanged from the prior year quarter. As Mike mentioned, the prior year quarter was a challenging comparison period, as it included approximately $0.4 million in back order fulfillment. Sequentially, third quarter revenue increased approximately 12% from the second quarter of 2026. Revenue for the first nine months of 2026 was $6.6 million, an increase of 13% from the prior year, driven by growth in U.S. circuit and console sales. Pediatric net sales increased 20% in the third quarter and 26% for the first nine months compared with the prior year periods. In the first nine months of 2026, we sold 32 consoles compared with 17 in the prior year period, an 88% increase.
During the quarter, the company sold eight Aquadex consoles compared with 12 in the third quarter of 2025. Gross profit for the third quarter of 2026 was approximately $1.5 million, resulting in a gross margin of 70% compared with 65% in the prior year quarter. The expanded margin improvement was driven by higher circuit and console average selling prices, favorable product mix, and the benefits of our transition to contract manufacturing. Operating expenses for the third quarter were approximately $3.6 million compared with approximately $4.1 million in the prior year quarter and approximately $4.7 million in the second quarter of 2026. The year-over-year decrease primarily reflects reductions in administrative costs and lower sales-related compensation. The sequential decrease reflects our continued efforts to align expenses with the company's highest priority commercial and strategic programs.
The combination of gross margin expansion and disciplined expense management resulted in a 24% year-over-year improvement in operating loss from approximately $2.7 million-$2.1 million. We remain focused on reducing operating expenses and cash utilization while continuing to invest in commercial and development programs that offer the greatest potential for long-term growth. Reported net loss for the third quarter was approximately $2 million compared with net income of approximately $0.5 million in the prior year quarter. The prior year result included a significant non-cash gain associated with changes in the fair value of warrant liabilities. Turning to the balance sheet, as of September 30th, 2026, the company had cash and cash equivalents of approximately $8.3 million, with runway through the second quarter of next year.
During the third quarter, we raised $3.4 million in gross proceeds through a registered direct offering in July and concurrently received $3.3 million in gross proceeds from the cash exercise of warrants. We also received $1.4 million in net proceeds from common shares sold under our at-the-market program. Looking ahead, our financial priorities remain unchanged: increasing recurring circuit revenue, reducing cash utilization, and directing capital toward the commercial and development programs with the greatest potential to create value. That concludes my prepared remarks. I will now turn the call back to Mike.
Thank you, Carisa. Before opening the call to questions, I want to take a second and just summarize where Nuwellis stands year-to-date. We have grown by double digits, nearly doubled our unit console sales, and significantly expanded our gross margin while reducing operating expenses and strengthening our balance sheet. In pediatrics, we have strengthened our clinical foundation with the ULTRA-Peds peer-reviewed publication, and we built on that evidence by submitting our 510(k) seeking expanded indications for the Aquadex to patients weighing as little as 5 kg. We are also advancing product development pipeline with SmartView and Pressure IQ that are expected to launch in 2027 while continuing to develop ClarityPRIME and exploring additional applications for that technology. We have broadened our commercial portfolio with agreements with Atrility Medical and Zorro-Flow, adding complementary products that leverage our existing sales force and customer relationships in a capital-efficient way.
We believe this progress positions Nuwellis for sustained growth and long-term value creation for patients, customers, and shareholders. We remain focused on disciplined execution and delivering measurable progress against each of these priorities. Operator, we would now like to open the call to any questions.
Thank you. If you would like to ask a question, please press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star and one to ask a question. We will pause for a moment to allow everyone a chance to join the queue. Once again, that is star and one if you would like to ask a question. We will pause for another moment. Once more, that is star and one to join the queue. At this time, we show no questions in queue. I will now turn the call back to Mike for some concluding remarks.
Thank you. We appreciate everybody's participation today in updating you on the third quarter results. We look forward to continue to update you on our progress and discussing the fourth quarter financial results at our next conference call early next year. Thank you again for joining us today.
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
Related articleQuarter not tagged2026-11-04Nuwellis to Report Third Quarter 2026 Financial Results on November 12
GlobeNewswire
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 12, 2026, and will host a conference call beginning at 9:00 a.m. Eastern time. Conference Call & Webcast Information Date: Thursday, November 12th Time: 9:00 a.m. Eastern time Domestic Dial-in: (833) 309-3473 International Dial-in: (785) 838-9251 Conference ID: NUWEQ3 Live and Replay Webcast: https://ir.nuwellis.com or available here About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis' portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com. For further information, please contact: Investor Relations: CORE IR [email protected] Media Contact: CORE PR [email protected]
Related articleQuarter not tagged2026-08-13Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
GlobeNewswire
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026. Second Quarter Results and Recent Highlights: Net sales were $2.0 million in the second quarter, a 14% increase compared with the prior-year period; U.S. revenue increased 17% Net sales for the first six months of 2026 were $4.4 million, a 20% increase compared with the prior-year period; U.S. revenue increased 24% Gross margin in the second quarter improved to 76%, compared with 56% in the prior-year quarter, reflecting improved pricing, product mix, and the transition to contract manufacturing Sold nine consoles during the second quarter and 24 during the first half of 2026, compared with five during the first half of 2025, expanding the installed base for future circuit utilization First-half revenue increased across all core customer categories compared with the prior-year period, led by a 29% increase in pediatrics, 28% in critical care, and 27% in heart failure. U.S. revenue growth outpaced the total Company average, which included lower international, service, and rental revenue. Raised $6.0 million in gross proceeds through a June registered direct offering Subsequent to June 30, 2026, raised approximately $6.7 million in gross proceeds from a July financing and warrant exercises, strengthening the Company’s cash position and simplifying its capitalization structure Advanced the proposed Aquadex label expansion to patients weighing 5 kilograms or more, from patients weighing 20 kilograms or more, following a successful U.S. Food and Drug Administration pre-submission meeting Appointed Mike McCormick as President and Chief Executive Officer, effective June 30, 2026 The second quarter demonstrated continued year-over-year growth, meaningful gross-margin improvement and progress across Nuwellis’ commercial and strategic priorities. The Company enters its next phase focused on increasing the installed based and utilization of Aquadex, building recurring circuit revenue, expanding its position in pediatrics and critical care, and selectively advanci…Read full documentShow less
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the three and six months ended June 30, 2026. Second Quarter Results and Recent Highlights: Net sales were $2.0 million in the second quarter, a 14% increase compared with the prior-year period; U.S. revenue increased 17% Net sales for the first six months of 2026 were $4.4 million, a 20% increase compared with the prior-year period; U.S. revenue increased 24% Gross margin in the second quarter improved to 76%, compared with 56% in the prior-year quarter, reflecting improved pricing, product mix, and the transition to contract manufacturing Sold nine consoles during the second quarter and 24 during the first half of 2026, compared with five during the first half of 2025, expanding the installed base for future circuit utilization First-half revenue increased across all core customer categories compared with the prior-year period, led by a 29% increase in pediatrics, 28% in critical care, and 27% in heart failure. U.S. revenue growth outpaced the total Company average, which included lower international, service, and rental revenue. Raised $6.0 million in gross proceeds through a June registered direct offering Subsequent to June 30, 2026, raised approximately $6.7 million in gross proceeds from a July financing and warrant exercises, strengthening the Company’s cash position and simplifying its capitalization structure Advanced the proposed Aquadex label expansion to patients weighing 5 kilograms or more, from patients weighing 20 kilograms or more, following a successful U.S. Food and Drug Administration pre-submission meeting Appointed Mike McCormick as President and Chief Executive Officer, effective June 30, 2026 The second quarter demonstrated continued year-over-year growth, meaningful gross-margin improvement and progress across Nuwellis’ commercial and strategic priorities. The Company enters its next phase focused on increasing the installed based and utilization of Aquadex, building recurring circuit revenue, expanding its position in pediatrics and critical care, and selectively advancing technologies that strengthen its broader cardiorenal platform. “Nuwellis has an established commercial foundation with differentiated strength in pediatrics and momentum in critical care. Our straightforward objective is to grow recurring revenue, improve operating leverage, and position Nuwellis as the leading precision fluid management company across the cardiorenal continuum,” said Mike McCormick, Nuwellis President and Chief Executive Officer. “The recent infusion of capital strengthens our balance sheet and extends our cash runway, which provides financial flexibility to execute on our strategic priorities. We intend to concentrate our investments where we have clear clinical differentiation, attractive commercial opportunities, and the ability to generate sustainable shareholder value. As part of our strategic plan, we are evaluating opportunities to leverage our commercial infrastructure through complementary products and collaborations that deepen relationships within our existing hospital customers.” Second Quarter 2026 Financial Results Revenue for the second quarter of 2026 was $2.0 million, compared with approximately $1.7 million in the prior-year quarter, representing a 14% increase. The increase was driven by higher U.S. circuit and console sales, partially offset by lower technical services, catheter, and international sales. The Company sold nine consoles during the second quarter, compared with three during the second quarter of 2025. The expanding installed base is expected to bolster growth in recurring circuit revenue, which remains the Company's primary driver of long-term growth. U.S. circuit and console average selling prices increased approximately 5% and 3%, respectively, compared with the prior-year quarter, reflecting pricing adjustments implemented during the third quarter of 2025. Gross margin for the second quarter of 2026 was 76%, compared with 56% in the prior-year quarter. The improvement reflected pricing adjustments implemented in 2025, favorable product mix, and our successful transition to contract manufacturing. Operating expenses were approximately $4.7 million for the second quarter of 2026, compared with $3.9 million in the prior-year period, reflecting planned investments in commercial expansion and product development. Net loss was approximately $4.8 million, including approximately $1.7 million of non-cash warrant valuation expense associated with the June 2026 financing, compared with a net loss of $12.6 million in the prior-year quarter. Following the effective date of the Company’s most recent reverse stock split on July 2, 2026, the related warrants were reclassified from liability to equity in early July. As of June 30, 2026, the Company had cash and cash equivalents of approximately $3.9 million. Through second-quarter financing activity and subsequent financing events, Nuwellis raised approximately $12.7 million in gross proceeds, strengthening its cash position and simplifying its capitalization structure. This activity included $6.0 million raised in June and, subsequent to June 30, an additional $3.4 million from a July financing and $3.3 million from warrant exercise proceeds. Webcast and Conference Call Information The Company will host a conference call and webcast at 9:00 a.m. Eastern time today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com/. Alternatively, the live conference call may be accessed by dialing (833) 316-1983 or (785) 838-9310 and using conference ID NUWEQ2. An audio archive of the webcast will be available following the call on the Investors page. About Aquadex The Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies. About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com. Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: Investor Relations: CORE [email protected] Media Contact: CORE [email protected]
Related articleQuarter not tagged2026-08-13Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...
GuruFocus.com
Nuwellis Inc (NUWE) (Q2 2026) Earnings Call Highlights: Revenue Surges 14% and Installed Base ...
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nuwellis Inc (NASDAQ:NUWE) reported a 14% increase in Q2 2026 revenue to $1.97 million, with U.S. revenue up 17%. The company sold 24 consoles in the first half of 2026, compared to only 5 in the same period of 2025, expanding its installed base. Gross margin improved significantly to 76% in Q2 2026, up from 56% in the prior-year quarter, driven by higher pricing and contract manufacturing benefits. Nuwellis Inc (NASDAQ:NUWE) is advancing its pediatric label expansion to include patients weighing 5 kg and above, with a planned FDA submission in Q4 2026. The company raised approximately $12.7 million in gross proceeds through financing activities, strengthening its cash position and simplifying its capital structure. Nuwellis Inc (NASDAQ:NUWE) received a notice of allowance for its dual-lumen midline catheter technology, which could support less invasive peripheral access for extracorporeal therapies. Nuwellis Inc (NASDAQ:NUWE) reported a net loss of approximately $4.8 million in Q2 2026, though improved from a $12.6 million loss in the prior-year quarter. Operating expenses increased to $4.7 million in Q2 2026, up from $3.9 million in the prior-year quarter, reflecting higher investment costs. The company's cash position remains low at $3.9 million as of June 30, 2026, despite subsequent financing efforts. Lower OUS service and rental revenue moderated overall revenue growth, indicating weakness in international markets. Nuwellis Inc (NASDAQ:NUWE) continues to rely on external financing to support operations, as evidenced by multiple capital raises in 2026. The company faces regulatory and development risks with its proposed pediatric label expansion and Clarity Prime product, which is not expected to launch until 2027. Warning! GuruFocus has detected 4 Warning Signs with NUWE. Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: What are the company's three essential objectives under the new CEO's mandate to drive growth and value?A: Mike McCormick, President and CEO, outlined three priorities: first, increase Aquadex utilization and recurrent circuit revenue by focusing on accounts and clinical pathways with sustained use; second, build the company's position in pedi…Read full documentShow less
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nuwellis Inc (NASDAQ:NUWE) reported a 14% increase in Q2 2026 revenue to $1.97 million, with U.S. revenue up 17%. The company sold 24 consoles in the first half of 2026, compared to only 5 in the same period of 2025, expanding its installed base. Gross margin improved significantly to 76% in Q2 2026, up from 56% in the prior-year quarter, driven by higher pricing and contract manufacturing benefits. Nuwellis Inc (NASDAQ:NUWE) is advancing its pediatric label expansion to include patients weighing 5 kg and above, with a planned FDA submission in Q4 2026. The company raised approximately $12.7 million in gross proceeds through financing activities, strengthening its cash position and simplifying its capital structure. Nuwellis Inc (NASDAQ:NUWE) received a notice of allowance for its dual-lumen midline catheter technology, which could support less invasive peripheral access for extracorporeal therapies. Nuwellis Inc (NASDAQ:NUWE) reported a net loss of approximately $4.8 million in Q2 2026, though improved from a $12.6 million loss in the prior-year quarter. Operating expenses increased to $4.7 million in Q2 2026, up from $3.9 million in the prior-year quarter, reflecting higher investment costs. The company's cash position remains low at $3.9 million as of June 30, 2026, despite subsequent financing efforts. Lower OUS service and rental revenue moderated overall revenue growth, indicating weakness in international markets. Nuwellis Inc (NASDAQ:NUWE) continues to rely on external financing to support operations, as evidenced by multiple capital raises in 2026. The company faces regulatory and development risks with its proposed pediatric label expansion and Clarity Prime product, which is not expected to launch until 2027. Warning! GuruFocus has detected 4 Warning Signs with NUWE. Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: What are the company's three essential objectives under the new CEO's mandate to drive growth and value?A: Mike McCormick, President and CEO, outlined three priorities: first, increase Aquadex utilization and recurrent circuit revenue by focusing on accounts and clinical pathways with sustained use; second, build the company's position in pediatrics and expand into adult critical care, areas with strong clinical relevance and commercial traction; and third, strategically broaden the cardiorenal platform through complementary technologies and collaborations that strengthen customer relationships and have a clear path to commercial value. Q: What is the status of the proposed FDA label expansion for Aquadex, and what is the timeline?A: Mike McCormick, President and CEO, stated that the company completed a pre-submission meeting with the FDA regarding expanding the Aquadex indication from patients 20 kilograms and above to those weighing five kilograms and above. The meeting provided clarity on the regulatory pathway, including bench testing, toxicology assessments, and pediatric clinical evidence. The company plans to submit the proposed label expansion to the FDA in the fourth quarter of 2026. Q: How did the company's financial performance in Q2 2026 compare to the prior year, and what drove the improvements?A: Carisa Schultz, CFO, reported that Q2 2026 revenue was $1.97 million, a 14% increase year-over-year, with U.S. revenue up 17%. Gross profit was approximately $1.5 million, resulting in a gross margin of 76%, a significant improvement from 56% in the prior-year quarter. This was driven by higher circuit and console average selling prices, favorable product mix, and the benefits of the transition to contract manufacturing. Q: What progress has been made in expanding the installed base of Aquadex consoles?A: Mike McCormick, President and CEO, highlighted that the company sold nine consoles in Q2 2026, bringing the first-half total to 24, compared to only five in the first half of 2025. Each placement expands the opportunity for recurrent circuit utilization. The focus is now on helping these accounts translate placements into sustained clinical use through training, protocol development, and early identification of appropriate patients. Q: What are the key developments in the pediatric segment, and how is the company expanding its footprint?A: Mike McCormick, President and CEO, noted that during the quarter, the company expanded its presence in a major South Carolina healthcare system and entered two new states, Michigan and Wisconsin, with their first pediatric programs. The company also celebrated five years of support for the Pediatric Cardiac Critical Care Consortium (PC4) and highlighted a case presented at the ISHLT meeting from the University of Iowa on using Aquadex for complex pediatric patients. Q: What is the company's strategy for adult critical care, and what initiatives are underway?A: Mike McCormick, President and CEO, discussed a strategic development initiative to expand Aquadex capabilities into broader extracorporeal therapy platforms, including higher flow capabilities for new filtration technologies and high-pressure environments. The company is also developing an enhanced user interface called Smart View to improve clinical workflows. During the quarter, over 280 physicians attended a critical care cardiac education summit with hands-on Aquadex training, one of the largest training initiatives in company history. Q: What is the status of the Clarity Prime product acquired with Renditech, and what is the expected launch timeline?A: Mike McCormick, President and CEO, stated that Clarity Prime, an automated kidney function monitoring system, is in the product development and technology integration phase. It has the potential to provide earlier and more continuous insights into kidney function changes. The company expects to launch Clarity Prime in 2027, which will complement Aquadex in providing stronger cardiorenal care solutions. Q: How is the company managing its cash position and capital allocation?A: Carisa Schultz, CFO, reported that as of June 30, 2026, the company had no debt and cash and cash equivalents of approximately $3.9 million. Subsequent to quarter end, the company raised an additional $3.4 million from a registered direct offering and $3.3 million from warrant exercises, strengthening the balance sheet. Mike McCormick emphasized capital discipline, focusing resources on Aquadex utilization, the pediatric label expansion, Clarity Prime development, and selected strategic opportunities. Q: What is the company's approach to evaluating complementary technologies for its cardiorenal platform?A: Mike McCormick, President and CEO, explained that the company is evaluating complementary pediatric technologies, including pediatric urine output monitoring and non-invasive cardiac monitoring. The approach will be selective and capital-efficient, only pursuing technologies that strengthen the company's position in pediatrics and critical care, complement existing customer relationships, and create a clear clinical and commercial benefit. Q: What recent intellectual property developments support the company's technology foundation?A: Mike McCormick, President and CEO, mentioned that the company received a notice of allowance from the U.S. Patent and Trademark Office for its dual-lumen midline catheter technology, which was issued in mid-July. This IP could support less invasive peripheral access for extracorporeal therapies and strengthens the technology foundation surrounding the fluid management platform. For the complete transcript of the earnings call, please refer to the full earnings call transcript.
TranscriptFY2026 Q22026-08-13FY2026 Q2 earnings call transcript
Earnings source - 21 paragraphs
FY2026 Q2 earnings call transcript
Good morning, and welcome to Nuwellis earnings conference call for the second quarter ended June 30, 2026. All participants are in listen-only mode. Should you need assistance, please signal a conferencing specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Participants on this call are advised that the audio of this conference call is being broadcast live over the internet and is being recorded for playback purposes. A replay of the call will be available approximately one hour after the end of the call. I would now like to turn the conference over to Leah McMullen, Director of Communications. Please go ahead.
Thank you, operator. Thank you for joining today's conference call to discuss Nuwellis' Corporate Developments and Financial Results for the Second Quarter ended June 30, 2026. Joining me today are Mike McCormick, Nuwellis' newly appointed President and Chief Executive Officer, and Carisa Schultz, Chief Financial Officer. Earlier today, Nuwellis released its financial results for the second quarter of 2026. If you have not received the earnings release, please visit the investor page on the company's website. During this conference call, the company will be making forward-looking statements. All forward-looking statements made during today's call will be protected under the Private Securities Litigation Reform Act of 1995. Any statements that relate to our expectations or predictions of future events and marketing trends, as well as our estimated results or performance, are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. Please refer to the cautionary statements and discussion of risk in the company's filings with the Securities and Exchange Commission, including the latest 10-K. With that, I would now like to turn the call over to Mike.
Thank you, Leah, and good morning, everyone. I am pleased to be joining you for my first earnings call as CEO of Nuwellis. I would like to begin by thanking John Erb for his leadership and for the work he has done to position the company for its next phase. John has transitioned his executive role. However, he still remains as Chairman of our board. Personally, having served on the board since 2023 and closely working with the company on its commercial strategy, I enter this role with a clear understanding of Nuwellis' strengths and where greater focus can create meaningful value. We have established a commercial therapy addressing an important clinical need, a growing installed base, strong relationships with leading institutions, and a differentiated position in precision fluid management. My mandate is to turn those strengths into a growing, scalable, and financially disciplined business.
We will do that by prioritizing three essential objectives. First, we intend to increase Aquadex utilization and recurrent circuit revenue by concentrating on accounts and clinical pathways where we can establish sustained use. Second, we intend to build our position in pediatrics and expand our presence in adult critical care, two areas where we see the strongest combination of clinical relevance and commercial traction as well as long-term growth opportunities. Third, we will endeavor to strategically broaden our cardiorenal platform through technologies and collaborations that complement the Aquadex, strengthen our existing customer relationships, and have a clear path toward commercial value. We believe the second quarter results showed progress across all of these priorities. An important commercial indicator of our continued expansion is the installed base.
During the second quarter, we sold nine consoles, bringing the first half total to 24, compared with only five in the first half of 2025. Each of those placements expands the opportunity for recurrent circuit utilization. Our focus is now on helping all of those accounts translate the placements into sustained clinical use through training, protocol development, and early identification of appropriate patients. We will measure progress not only by the consoles placed but by the number of accounts achieving consistent utilization, the number of patients treated, and recurring circuit revenue generated from the installed base. Pediatrics remained the clearest example of this strategy in action. During the quarter, we expanded our presence in a major South Carolina healthcare system, and we expanded into two new states with the first pediatric programs in their history. We opened in Michigan and also in Wisconsin.
We continue to strengthen the educational foundation supporting pediatric adoption. At the International Society for Heart and Lung Transplantation 46th Annual Meeting and Scientific Sessions, clinicians from the University of Iowa presented a case that highlighted the Aquadex use in managing recurrent fluid overload in a very complex pediatric cardiac patient. We also marked five years of support for the Pediatric Cardiac Critical Care Consortium, or PC4, a collaborative network focused on improving outcomes for critically ill pediatric cardiac patients. From a product standpoint, we continue to enhance the Aquadex platform with software updates designed to improve workflow efficiency, support treatment precision, and reduce barriers to therapy use. We also completed a pre-submission meeting with the FDA regarding a proposed expansion of the Aquadex indication for patients from 20 kg and above, which it is today, to patients weighing 5 kg and above.
This meeting provided greater clarity regarding the proposed regulatory pathway. That includes bench testing, toxicology assessments, and supporting pediatric clinical evidence. We plan to submit the proposed label expansion to the FDA in the fourth quarter of this year. Together, these developments create a focused pediatric growth strategy, expand our commercial footprint, increase utilization within existing programs, improve products for smaller patients, and pursue a regulatory pathway that can meaningfully broaden the population that we serve. Critical care represents another significant opportunity for us. We recently announced the strategic development initiative to expand the capabilities of the Aquadex into broader extracorporeal therapy platform. These initiatives include higher flow capabilities designed to support new filtration technologies and expand the potential use of Aquadex in more complex critical care, high-pressure extracorporeal environments.
We are also developing an enhanced user interface called SmartView that will make the Aquadex easier to use, improve clinical workflows, and support greater utilization. Together, these development programs are intended to broaden the capabilities of Aquadex and to strengthen our position in critical care. During the quarter, more than 280 physicians attended a critical care cardiac education summit that included hands-on training with the Aquadex. That created one of the largest concentrated physician training initiatives in the company's history. Our next step is to connect that growing clinical awareness with focused account development. We see an opportunity with our broader cardiorenal strategy to build from the same customer relationships and area of clinical expertise. The acquisition of Rendiatech in the first quarter of 2026 added ClarityPRIME, an automated kidney function monitoring system to our development portfolio.
During the second quarter, our focus was on product development and technology integration and commercial planning. Aquadex gives clinicians the ability to remove excess fluid with precision. ClarityPRIME has the potential to provide earlier and more continuous insights, allowing early detection of changes in kidney function. We expect this important ClarityPRIME product to launch in 2027. Together, these technologies support stronger solutions to cardiorenal care in which clinicians can make better-informed decisions about fluid balance and kidney function. To further broaden our product offering and leverage our commercial infrastructure, we are evaluating complementary pediatric technologies, including pediatric urine output monitoring and pediatric non-invasive cardiac monitoring. Our approach will remain selective and capital efficient. We expect to only pursue technologies and collaborations that strengthen our position in pediatrics and critical care, complement the customer relationships we already have, and create a clear clinical and commercial benefit.
During the quarter, we also received a notice of allowance from the United States Patent and Trademark Office for our dual lumen midline catheter technology. This intellectual property could support less invasive peripheral access for extracorporeal therapies, and it strengthens the technology foundation surrounding our fluid management platform. That patent, in fact, issued in mid-July. Excuse me. Capital discipline will remain central to the way that we operate. We intend to concentrate resources around Aquadex utilization, the proposed pediatric label expansion, focused development of ClarityPRIME, and selected strategic opportunities that directly support our strategy. Nuwellis has an established commercial foundation, differentiated strength in pediatrics, a growing traction in critical care, and a focused strategy to expand our role in cardiorenal care. While we do not provide formal financial guidance, our objectives remain clear.
Deliver consistent double-digit revenue growth, maintain strong gross margins, increase our installed base and recurring circuit utilization, and advance our highest priority development programs to reduce and reduce cash utilization over time. In addition, through June financing and subsequent to the end-of-the-quarter financing events, we raised approximately $12.7 million in gross proceeds. That included $6 million in June. That was a private placement, and subsequent to the end of the quarter, we raised an additional $3.4 million from a registered direct offering and $3.3 million from warrant exercises. These actions strengthened our cash position, and it simplified our capitalization structure. With that, I am pleased to turn the call over to Carisa Schultz, who is our Chief Financial Officer, for a detailed review of our financial results. Carisa?
Thank you, Mike, and good morning. I will review our second quarter and year-to-date financial performance and balance sheet position. Revenue for the second quarter of 2026 was $1.97 million, compared with approximately $1.7 million in the prior year quarter, representing an increase of 14%, while U.S. revenue increased 17%. Revenue for the first six months of 2026 was $4.37 million, an increase of 20% from the prior year, while U.S. revenue increased 24%. Lower OUS service and rental revenue moderated reported growth, while U.S. revenue growth outpaced total company growth. During the quarter, the company sold nine U.S. consoles, compared with three in the second quarter of 2025. The new console placements, including within pediatric programs, expanded the installed base and created additional opportunities for sustained Aquadex utilization.
U.S. circuit average selling prices increased approximately 5% compared with the prior year quarter, and console average selling prices increased approximately 3%. These increases primarily reflect pricing adjustments implemented during the third quarter of 2025. Gross profit for the second quarter was approximately $1.5 million, resulting in a gross margin of 76%, compared with 56% in the prior year quarter. The 20 percentage point improvement was driven by higher circuit and console average selling prices, favorable product mix, and the benefits of our transition to contract manufacturing. Operating expenses for the second quarter were approximately $4.7 million, compared with approximately $3.9 million in the prior year quarter and approximately $6.3 million in the first quarter of 2026. The year-over-year increase primarily reflects investments supporting commercial expansion and product development initiatives. The sequential decrease reflects our continued effort to align expenses with the company's highest priority commercial and strategic programs.
Reported net loss for the second quarter was approximately $4.8 million, compared with approximately $12.6 million in the prior year quarter. The second quarter result included approximately $1.7 million of warrant valuation expense associated with the June 2026 financing. Following the effective date of the company's most recent reverse stock split on July 2nd, 2026, the related warrants were reclassified from liability to equity in early July. During June, the company completed a $6 million registered public offering. As of June 30th, 2026, the company had no debt, and cash and cash equivalents were approximately $3.9 million. As Mike previously mentioned, subsequent to quarter end, we further strengthened our balance sheet. In July, we raised an additional $3.4 million in gross proceeds through a registered direct offering and received $3.3 million from the cash exercise of warrants in connection with the June 2026 financing.
As we move through the second half of the year, our financial priorities remain focused on increasing recurring circuit revenue, maintaining gross margin discipline, reducing cash utilization, and directing capital toward the commercial and development programs with the greatest potential to create value. That concludes my prepared remarks. I will now turn the call back to Mike.
Thank you, Carisa Schultz. Before opening the call to questions, I want to reinforce the strategic direction we have outlined today. Nuwellis has an established commercial foundation with a clear pathway to growth. Our focus is to increase the Aquadex installed base, utilization, and recurrent circuit revenue within the accounts and clinical categories where we can establish sustained use. We intend to continue building differentiated position in pediatrics through commercial expansion, product improvements, clinical evidence, and proposed label expansion. We intend to grow our presence in adult critical care by connecting clinical education with focused account development and stronger pathways for Aquadex use. We are expected to selectively advance ClarityPRIME, our complementary technology that will broaden the relevance across fluid management and kidney function monitoring.
These priorities are designed to create a stronger recurring revenue base, expand the patients and clinicians that we serve, as well as build more value in our cardiorenal platform. We will pursue them with a disciplined capital allocation and clear expectation of measurable progress. Operator, we would now like to open the call to any questions.
Thank you. If you would like to ask a question, press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star one to ask a question. We will pause for just a moment to allow everyone a chance to join the queue. At this time, we have no questions in the queue. I will now turn the call back to Mike McCormick for concluding remarks.
Thank you very much. We look forward to updating everyone on our progress and discussing our third quarter financial results on our next conference call that will be scheduled in November. Thank you again for joining us today.
Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.
Related articleQuarter not tagged2026-07-27Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
GlobeNewswire
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report second quarter 2026 financial results on August 13 MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for its second quarter ended June 30, 2026, with revenue year-over-year growth of 14% for the second quarter of 2026 and 20% for the first six months of 2026. Management expects to report its financial results for the three and six months ended June 30, 2026, before the open of the U.S. financial markets on August 13th and will host a conference call and webcast beginning at 9:00 a.m. Eastern time. "Our second quarter preliminary revenue results reflect continued commercial momentum and the outstanding execution of our entire Nuwellis team," said Mike McCormick, Nuwellis Chief Executive Officer. "Revenue growth of 20% during the first half of 2026 demonstrates the increasing adoption of Aquadex and the progress we are making in executing our long-term growth strategy. During our earnings call, we look forward to reviewing our financial performance, and discussing our commercial initiatives, product development programs, and strategic partnerships. Additionally, we will highlight opportunities we believe position us for continued growth through the remainder of 2026 and into next year." The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed in greater detail during its financial results conference call. Conference Call & Webcast Information Date: August 13, 2026Time: 9:00 a.m. Eastern TimeDial-in: 1-833-316-1983 or 1-785-838-9310Conference ID: NUWEQ2 To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com or access here. An audio archive of the webcast will be available following the call on the Investors page. About AquadexThe Aquadex SmartFlow System is indicated for the continuous…Read full documentShow less
Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report second quarter 2026 financial results on August 13 MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced unaudited preliminary results for its second quarter ended June 30, 2026, with revenue year-over-year growth of 14% for the second quarter of 2026 and 20% for the first six months of 2026. Management expects to report its financial results for the three and six months ended June 30, 2026, before the open of the U.S. financial markets on August 13th and will host a conference call and webcast beginning at 9:00 a.m. Eastern time. "Our second quarter preliminary revenue results reflect continued commercial momentum and the outstanding execution of our entire Nuwellis team," said Mike McCormick, Nuwellis Chief Executive Officer. "Revenue growth of 20% during the first half of 2026 demonstrates the increasing adoption of Aquadex and the progress we are making in executing our long-term growth strategy. During our earnings call, we look forward to reviewing our financial performance, and discussing our commercial initiatives, product development programs, and strategic partnerships. Additionally, we will highlight opportunities we believe position us for continued growth through the remainder of 2026 and into next year." The financial information in this release is unaudited and subject to adjustment and confirmation as the Company completes its quarterly review and finalizes its financial statements to be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and discussed in greater detail during its financial results conference call. Conference Call & Webcast Information Date: August 13, 2026Time: 9:00 a.m. Eastern TimeDial-in: 1-833-316-1983 or 1-785-838-9310Conference ID: NUWEQ2 To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com or access here. An audio archive of the webcast will be available following the call on the Investors page. About AquadexThe Aquadex SmartFlow System is indicated for the continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies. About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com. Forward-Looking StatementsCertain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise. For further information, please contact: Investor Relations: CORE [email protected] Media Contact: CORE [email protected]
Related articleQuarter not tagged2026-05-13Nuwellis, Inc. Q1 2026 Earnings Call Summary
Moby
Nuwellis, Inc. Q1 2026 Earnings Call Summary
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterized Q1 2026 as the transition from a 2025 structural reset to active strategic execution, focusing on the cardiorenal care continuum. Revenue growth of 26% was attributed to a significant increase in console sales and continued expansion of circuit sales, indicating higher patient treatment volumes. Gross margin expansion to 70.1% was driven by a combination of improved pricing strategies, favorable product mix, and the operational transition to contract manufacturing at KDI. The pediatric segment has become a primary growth engine, now representing approximately 50% of total U.S. revenue with a footprint in 47 centers nationwide. Strategic leadership changes, including a new CFO and board appointments, were implemented to instill greater rigor in forecasting and capital allocation. The acquisition of RendiaTech is intended to evolve the company from a fluid removal specialist to a broader provider of automated kidney function monitoring. Management is developing a cash burn reduction plan aimed at reducing monthly cash burn by approximately 50% by the fourth quarter of 2026. Future pediatric innovation is centered on the 'Vivien' CRRT system, supported by a new U.S. patent for advanced safety design in extracorporeal therapy. The company plans to develop a highly differentiated bedside kidney monitoring product from the RendiaTech acquisition for a projected U.S. market introduction in 2027. Sales strategy involves deepening utilization in high-priority accounts by leveraging experienced sales leaders returned to the company in key territories like South Texas. Completed an approximately $5 million private placement and warrant inducement transaction to bolster the capital foundation for ongoing operations. Operating expenses increased to approximately $6 million, primarily due to higher sales headcount and compensation tied to increased commercial activity. The company reported having no debt as of March 31, 2026, with approximately $2.2 million in cash and restricted cash equivalents. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management highlighted the return of a top-performing sales representative to lead the new South Tex…Read full documentShow less
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterized Q1 2026 as the transition from a 2025 structural reset to active strategic execution, focusing on the cardiorenal care continuum. Revenue growth of 26% was attributed to a significant increase in console sales and continued expansion of circuit sales, indicating higher patient treatment volumes. Gross margin expansion to 70.1% was driven by a combination of improved pricing strategies, favorable product mix, and the operational transition to contract manufacturing at KDI. The pediatric segment has become a primary growth engine, now representing approximately 50% of total U.S. revenue with a footprint in 47 centers nationwide. Strategic leadership changes, including a new CFO and board appointments, were implemented to instill greater rigor in forecasting and capital allocation. The acquisition of RendiaTech is intended to evolve the company from a fluid removal specialist to a broader provider of automated kidney function monitoring. Management is developing a cash burn reduction plan aimed at reducing monthly cash burn by approximately 50% by the fourth quarter of 2026. Future pediatric innovation is centered on the 'Vivien' CRRT system, supported by a new U.S. patent for advanced safety design in extracorporeal therapy. The company plans to develop a highly differentiated bedside kidney monitoring product from the RendiaTech acquisition for a projected U.S. market introduction in 2027. Sales strategy involves deepening utilization in high-priority accounts by leveraging experienced sales leaders returned to the company in key territories like South Texas. Completed an approximately $5 million private placement and warrant inducement transaction to bolster the capital foundation for ongoing operations. Operating expenses increased to approximately $6 million, primarily due to higher sales headcount and compensation tied to increased commercial activity. The company reported having no debt as of March 31, 2026, with approximately $2.2 million in cash and restricted cash equivalents. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management highlighted the return of a top-performing sales representative to lead the new South Texas territory, specifically targeting the Houston area. The Northeast remains the strongest regional performer, while the Western territory is seeing early traction particularly in pediatric accounts like Seattle Children's. The acquisition was driven by a product in development that monitors kidney output and analytes at the bedside, providing immediate data compared to traditional lab reports. Management clarified that RendiaTech products have not yet been introduced to the U.S. market by Nuwellis; the target product is currently in development for a 2027 launch. Management confirmed the company sold 15 Aquadex units during the first quarter, which included upgrades to SmartFlow systems and new placements in both pediatric and adult accounts.
Related articleQuarter not tagged2026-05-13Nuwellis Inc (NUWE) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com
Nuwellis Inc (NUWE) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Revenue for the first quarter increased by 26% year-over-year, driven by stronger console and circuit sales. Gross margin improved to 70.1%, reflecting better pricing, product mix, and transition to contract manufacturing. The company completed a strategic acquisition of RendiaTek, enhancing its product development portfolio with automated kidney function monitoring capabilities. Pediatrics now represents approximately 50% of total U.S. revenue, with an expanded footprint in 47 centers nationwide. The appointment of experienced leaders, including a new CFO and board members, strengthens the company's leadership and governance. Operating expenses increased to approximately $6 million, up from $4.1 million in the prior-year quarter, due to higher sales headcount and compensation. Net loss attributable to common shareholders was approximately $4.3 million for the first quarter. The company had cash and restricted cash equivalents of only $2.2 million as of March 31, 2026, indicating limited liquidity. The integration of RendiaTek's technology is still in development, with no immediate introduction to the U.S. market until 2027. Despite revenue growth, the company is still in the early stages of executing its strategic plan, with more work ahead to achieve consistent execution. Warning! GuruFocus has detected 3 Warning Signs with NUWE. Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: Can you discuss the new commercial coverage in the South Texas territory and any other regions targeted for expansion? A: John Erb, CEO, explained that the South Texas territory is promising due to the return of a top sales rep, Libby, who previously built the New York territory. The territory was split to allow Libby to focus on the southern part, while another rep covers the northern part. The Northeast, particularly New York and the Washington-Philadelphia area, remains a strong growth area, with new pediatric accounts like Children's Hospital of Philadelphia. The western territory, especially in Seattle, is also a focus area. Q: Can you provide details on the integration with RendiaTek and how you are presenting these offerings to your current customer base? A: John Erb, CEO, stated that…Read full documentShow less
This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Revenue for the first quarter increased by 26% year-over-year, driven by stronger console and circuit sales. Gross margin improved to 70.1%, reflecting better pricing, product mix, and transition to contract manufacturing. The company completed a strategic acquisition of RendiaTek, enhancing its product development portfolio with automated kidney function monitoring capabilities. Pediatrics now represents approximately 50% of total U.S. revenue, with an expanded footprint in 47 centers nationwide. The appointment of experienced leaders, including a new CFO and board members, strengthens the company's leadership and governance. Operating expenses increased to approximately $6 million, up from $4.1 million in the prior-year quarter, due to higher sales headcount and compensation. Net loss attributable to common shareholders was approximately $4.3 million for the first quarter. The company had cash and restricted cash equivalents of only $2.2 million as of March 31, 2026, indicating limited liquidity. The integration of RendiaTek's technology is still in development, with no immediate introduction to the U.S. market until 2027. Despite revenue growth, the company is still in the early stages of executing its strategic plan, with more work ahead to achieve consistent execution. Warning! GuruFocus has detected 3 Warning Signs with NUWE. Is NUWE fairly valued? Test your thesis with our free DCF calculator. Q: Can you discuss the new commercial coverage in the South Texas territory and any other regions targeted for expansion? A: John Erb, CEO, explained that the South Texas territory is promising due to the return of a top sales rep, Libby, who previously built the New York territory. The territory was split to allow Libby to focus on the southern part, while another rep covers the northern part. The Northeast, particularly New York and the Washington-Philadelphia area, remains a strong growth area, with new pediatric accounts like Children's Hospital of Philadelphia. The western territory, especially in Seattle, is also a focus area. Q: Can you provide details on the integration with RendiaTek and how you are presenting these offerings to your current customer base? A: John Erb, CEO, stated that RendiaTek has not been introduced to the U.S. market yet. The acquisition was primarily for a product in development that monitors kidney output, which will be developed further. This product will provide immediate readings of electrolyte balances at the bedside, differentiating it from current market offerings. The product is expected to be introduced in the U.S. market in 2027. Q: How many Aquadex units were sold in the first quarter? A: John Erb, CEO, confirmed that 15 Aquadex units were sold in the first quarter. Q: What are the financial priorities moving forward? A: Carissa Schultz, CFO, emphasized that the financial priorities include disciplined capital deployment, maintaining gross margin consistency, commercial execution, and enhancing visibility into utilization and account growth drivers. Q: What are the main strategic focuses for Nuwellis in 2026? A: John Erb, CEO, highlighted that the focus is on supporting Aquadex utilization in areas with strong clinical adoption, advancing the integration of RendiaTek, strengthening the pediatric strategy, and maintaining financial discipline. The company aims to build on its cardiorenal platform and expand its clinical relevance in pediatrics and critical care. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

